secwatch.observer — SEC 8-K summary
======================================

Issuer:     EyePoint, Inc. (EYPT)
CIK:        0001314102
Form:       8-K
Filed at:   2023-12-08T23:59:59+00:00
Accession:  0001193125-23-290820
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EyePoint prices $200M public offering at $17/share to fund Phase 3 trials for EYP-1901
--------------------------------------------------------------------------------

- Underwritten public offering of 11,764,706 shares priced at $17.00 per share; underwriters exercised option for additional 1,764,705 shares.
- Expected net proceeds ~$215.9M after underwriting discounts and expenses.
- Proceeds to fund two pivotal Phase 3 trials of EYP-1901 for wet AMD and other pipeline initiatives.
- Closing expected December 8, 2023; J.P. Morgan, TD Cowen, Guggenheim lead underwriters.
- Offering upsized from initial $175M to ~$200M gross.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314102/000119312523290820/0001193125-23-290820-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314102/000119312523290820/d627747d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-290820

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer